RSSCategory: Recent News

FDA Approves Sonidegib for Some Patients with Advanced Basal Cell Carcinoma

| July 8, 2017 | 0 Comments

FDA Approves Sonidegib for Some Patients with Advanced Basal Cell Carcinoma The FDA has approved sonidegib for the treatment of patients with locally advanced basal cell carcinoma.See Original Article The RAS Problem: Turning Off a Broken Switch The RAS gene is commonly mutated in cancer and researchers are working to better understand how to develop […]

Continue Reading

New on NCI’s Websites

| July 8, 2017 | 0 Comments

New on NCI’s Websites NCI periodically provides updates on new websites and other online content of interest to the cancer community.See Original Article Overdiagnosis of Cancer: Bringing an Important Problem into Focus Experts are convening for a conference on the dilemmas posed by overdiagnosis in many types of diseases. Overdiagnosis is generally defined as the […]

Continue Reading

Supporting Vice President Biden's Cancer Initiative

| July 8, 2017 | 0 Comments

Supporting Vice President Biden's Cancer Initiative During his 2016 State of the Union address to Congress, President Obama tasked Vice President Biden with leading a new initiative to accelerate cancer research. This message from NCI Acting Director Doug Lowy states that the Institute stands ready to work with partners across the cancer research community on […]

Continue Reading

Improving Cancer Control in Rural Communities: Next Steps

| July 7, 2017 | 0 Comments

Improving Cancer Control in Rural Communities: Next Steps Studies continue to show disparities in cancer outcomes for people who live in rural parts of the United States. NCI’s Dr. Robert Croyle explains how the institute is working with multiple partners to better understand and address these disparities.See Original Article

Continue Reading

Cancer Researchers Report Progress in Studying Exceptional Responders

| July 6, 2017 | 0 Comments

Cancer Researchers Report Progress in Studying Exceptional Responders Researchers who study exceptional responders—patients who have dramatic and long-lasting responses to treatments for cancer that were not effective for most similar patients—met recently to discuss the state of the science in this emerging field. See Original Article

Continue Reading

RAS and MYC – co-conspirators in cancer

| July 3, 2017 | 0 Comments

RAS and MYC – co-conspirators in cancer The transcription factor MYC is an important downstream target of mutated RAS genes in human cancers. Inhibiting post-translational modifications of MYC to decrease its transcriptional activity is a new strategy for treating RAS-driven cancers.See Original Article

Continue Reading

Mutations Linked to Immunotherapy Resistance

| July 2, 2017 | 0 Comments

Mutations Linked to Immunotherapy Resistance Researchers identified mutations in relapsed melanoma tumors that block the anticancer effects of the checkpoint inhibitor pembrolizumab.See Original Article Study Confirms Benefits of Early Palliative Care for Advanced Cancer A randomized clinical trial has found that patients who received palliative care along with standard treatment for advanced cancer reported having […]

Continue Reading

Extensive Lymph Node Surgery Does Not Increase Survival in Melanoma

| June 30, 2017 | 0 Comments

Extensive Lymph Node Surgery Does Not Increase Survival in Melanoma A conservative approach to lymph node removal surgery may be best for people with melanoma that has spread from the skin to one or a small number of nearby lymph nodes, new results from a large international clinical trial suggest. See Original Article

Continue Reading

Introducing DAVE: Online Analysis Tools for the Genomic Data Commons

| June 29, 2017 | 0 Comments

Introducing DAVE: Online Analysis Tools for the Genomic Data Commons NCI has released an online, open-access cancer research resource for the Genomic Data Commons called the Data Analysis, Visualization, and Exploration Tools, or DAVE.See Original Article

Continue Reading

Blinatumomab Extends Survival for Patients with Advanced ALL

| June 28, 2017 | 0 Comments

Blinatumomab Extends Survival for Patients with Advanced ALL Patients with previously treated acute lymphoblastic leukemia who received blinatumomab, which encourages the immune system to kill cancer cells, lived longer and experienced fewer side effects than patients given standard chemotherapy.See Original Article

Continue Reading